Investigation of the in Vitro Metabolism of the Analgesic Flupirtine

@article{Methling2009InvestigationOT,
  title={Investigation of the in Vitro Metabolism of the Analgesic Flupirtine},
  author={Karen Methling and Przyemslaw Reszka and Michael Lalk and Oldřich Vrána and Eberhard Scheuch and Werner Siegmund and Bernd Terhaag and Patrick J. Bednarski},
  journal={Drug Metabolism and Disposition},
  year={2009},
  volume={37},
  pages={479 - 493}
}
The in vitro metabolism of flupirtine, ethyl-N-[2-amino-6-(4-fluorophenylmethyl-amino)pyridine-3-yl]carbamate, a centrally acting analgesic with muscle tone-reducing activity, was studied. Two flupirtine metabolites were already known: the N-acetylated analog D13223 and 4-fluorohippuric acid. The structure of flupirtine suggested that redox chemistry may play a role in metabolism, and cyclic voltammetry studies showed that the drug undergoes facile and irreversible redox reactions. Thus… 

Tables from this paper

Oxidation Potentials of N‐Modified Derivatives of the Analgesic Flupirtine Linked to Potassium KV7 Channel Opening Activity But Not Hepatocyte Toxicity

The idea that oxidative metabolites of flupirtine contribute to the mechanism of action, similar to what was recently proposed for acetaminophen, but not to hepatotoxicity, is supported.

Flupirtine as a Potential Treatment for Fibromyalgia

Evidence that flupirtine, or related drugs, is a therapeutic option for the treatment of fibromyalgia is presented.

Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.

Formation of mercapturic acid derivatives is a major elimination route for flupirtine in man and the theoretically toxic pathway is not influenced by the frequent polymorphisms of UGT1A1, NAT2 and GSTP1.

Modifications of the Triaminoaryl Metabophore of Flupirtine and Retigabine Aimed at Avoiding Quinone Diimine Formation

A drug design strategy of avoiding the detrimental oxidation of the central aromatic ring by shifting oxidation toward the formation of benign metabolites was followed, and an alternative retrometabolic design strategy was followed.

Concise review: Therapeutic potential of flupirtine maleate

The pain-relieving property of flupirtine is not reduced by the opioid antagonistic drug naloxone, preliminary finding require confirmation in further comparative studies.

Brain Distribution and Metabolism of Flupirtine, a Nonopioid Analgesic Drug with Antiseizure Effects, in Neonatal Rats

Tissue partition coefficients based on isolated tissue uptake correlated well with in vivo tissue:serum drug exposure ratios and flupirtine reaches the target brain tissues from the systemic route in neonatal rats, and brain tissue forms the active metabolite D-13223.

Sulfide Analogues of Flupirtine and Retigabine with Nanomolar KV7.2/KV7.3 Channel Opening Activity

The potassium channel openers flupirtine and retigabine have proven to be valuable analgesics or antiepileptics. Their recent withdrawal due to occasional hepatotoxicity and tissue discoloration,

Pharmacology and clinical applications of flupirtine: Current and future options

  • K. Lawson
  • Biology, Medicine
    World Journal of Pharmacology
  • 2019
Flupirtine is providing important information and clues regarding novel mechanistic approaches to the treatment of a range of clinical conditions involving hyper-excitability of cells, and identification of molecules exhibiting specificity for the pharmacological targets involved in the actions of fl upirtine will provide further insight into clinical applications.

Bioanalytical Method Validation and Quantification of Flupirtine in Canine Plasma by HPLC with Spectrofluorimetric Detection

Flupirtine (FLU) is a non-opioid analgesic drug belongs to the class of N-Methyl-D-Aspartate (NMDA) antagonist without antipyretic or antiphlogistic properties. No analytical method to detect FLU in

References

SHOWING 1-10 OF 46 REFERENCES

[Pharmacokinetics and biotransformation of the analgesic flupirtine in humans].

The pharmacokinetics of the analgesic flupirtine were examined in healthy volunteers after a single intravenous, peroral and rectal dose and two metabolites could be isolated from urine and their chemical structure determined.

Metabolism of retigabine (D-23129), a novel anticonvulsant.

Plasma profiling and spectroscopic analysis of two isolated urinary metabolites obtained after single oral dosing of 600 mg retigabine in healthy volunteers indicated that both acetylation and glucuronidation are major metabolic pathways of retigABine in humans.

The action of flupirtine on prostaglandin formation and platelet aggregation in vitro.

The action of ethyl-N-(2-amino-6-(4-fluorophenylmethylamino) pyridin - 3 - yl) carbamate (flupirtine, D 9998), a recently synthesized analgesic, on prostaglandin formation and platelet aggregation

Antioxidant properties of the triaminopyridine, flupirtine.

[The pharmacologic effect of flupirtine, a structurally new analgesic].

Flupirtine does not develop tolerance in mice and rats after 19 or 17 days of daily administration and exhibits a distinct central analgesic component of action, which corresponds to that of opiate properties and other potent analgesics.

In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices.

The metabolic profile of D-23129, a new anticonvulsant agent, was studied in vitro using human liver microsomes and fresh liver slices and phase II conjugation dominated the metabolism producing two distinct N-glucuronides as the primary metabolites.

Flupirtine: A Review of Its Neuroprotective and Behavioral Properties

It has been discovered that flupirtine, in a clinically relevant dosage range, has potent cytoand neuroprotective potential as well as anticonvulsant, and myorelaxant effects.

Influence of propiverine on hepatic microsomal cytochrome p450 enzymes in male rats.

Propiverine is a phenobarbital-type inducer on hepatic P450 enzymes in rats in doses about 100-times above the therapeutic doses in man.

Species differences in N-glucuronidation.

  • S. H. ChiuS. Huskey
  • Biology
    Drug metabolism and disposition: the biological fate of chemicals
  • 1998
Glucuronidation of amines has been shown to exhibit species differences in vitro and in vivo. Substrates for N-glucuronidation can be classified according to the chemical structures of the resulting